Skip to Content
Merck
CN

SML2522

Diprovocim-1

≥98% (HPLC)

Synonym(s):

(3S,3′S,4S,4′S)-1,1′-(1,4-Phenylenedicarbonyl)bis[N-[(1S,2R)-2-phenylcyclopropyl]-3,4-pyrrolidinedicarboxamide, 3,4-Pyrrolidinedicarboxamide, 1,1′-(1,4-phenylenedicarbonyl)bis[N-[(1S,2R)-2-phenylcyclopropyl]-, (3S,3′S,4S,4′S)-

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C56H56N6O6
CAS Number:
2170867-89-5
Molecular Weight:
909.08
UNSPSC Code:
51111800
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

ABZBNXFGYUSVCJ-UYMKNZQYSA-N

SMILES string

N7(C[C@H]([C@@H](C7)C(=O)N[C@@H]%10[C@H](C%10)c%11ccccc%11)C(=O)N[C@@H]8[C@H](C8)c9ccccc9)C(=O)c1ccc(cc1)C(=O)N2C[C@H]([C@@H](C2)C(=O)N[C@@H]5[C@H](C5)c6ccccc6)C(=O)N[C@@H]3[C@H](C3)c4ccccc4

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

Related Categories

Biochem/physiol Actions

Agonist of toll-like receptors TLR2 and TLR1
Diprovocim-1 is a potent agonist of toll-like receptors TLR2 and TLR1 with an EC50 value of 100 pM. Diprovocim-1 was shown to synergize with anti-PD-L1 treatment, inhibiting tumor growth, generating long-term antitumor memory, and curing or prolonging survival of mice engrafted with the murine melanoma B16-OVA.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000184420
0000184419
0000184419
0000184420
0000074049

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ying Wang et al.
Proceedings of the National Academy of Sciences of the United States of America, 115(37), E8698-E8706 (2018-08-29)
Successful cancer immunotherapy entails activation of innate immune receptors to promote dendritic cell (DC) maturation, antigen presentation, up-regulation of costimulatory molecules, and cytokine secretion, leading to activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs). Here we screened a synthetic library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service